1225586-54-8 Usage
Description
1-(1-Propyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone is a synthetic compound belonging to the class of organic compounds known as pyrrolopyridines. It is a ketone derivative featuring a propyl substituent at the 1-position and a pyrrolo[2,3-c]pyridine moiety at the 3-position. 1-(1-Propyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone exhibits potential biological activities and is of interest in the pharmaceutical industry for its possible applications as a pharmaceutical intermediate or in drug discovery research. Careful handling, storage, and disposal are advised due to potential hazards associated with this chemical.
Uses
Used in Pharmaceutical Industry:
1-(1-Propyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone is used as a pharmaceutical intermediate for its potential role in the development of new drugs. Its unique chemical structure allows for further modification and synthesis of more complex molecules with therapeutic potential.
Used in Drug Discovery Research:
In the field of drug discovery, 1-(1-Propyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone serves as a valuable compound for exploring its biological activities and potential therapeutic applications. Its structure may be optimized to target specific biological pathways or receptors, leading to the creation of novel pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1225586-54-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,5,5,8 and 6 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1225586-54:
(9*1)+(8*2)+(7*2)+(6*5)+(5*5)+(4*8)+(3*6)+(2*5)+(1*4)=158
158 % 10 = 8
So 1225586-54-8 is a valid CAS Registry Number.
1225586-54-8Relevant articles and documents
KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS
-
, (2011/11/06)
Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases
